论文部分内容阅读
目的探讨终末期肝病模型评分系统在晚期肝癌患者介入治疗中的应用价值。方法 58例肝癌晚期患者按照终末期肝病模型评分分成研究1组30例(评分30~39分)和研究2组28例(评分≥40分),两组患者均给予晚期肝癌介入治疗,对比两组患者治疗前后的临床生化指标情况和介入治疗3个月后的病死率,分析患者临床生化指标变化情况和病死率与终末期肝病模型评分的关系。结果研究1组患者的临床生化指标改善情况明显优于研究2组(P<0.05);研究2组患者的病死率明显高于研究1组(P<0.05)。结论终末期肝病模型评分可用于评价晚期肝癌患者肝功能情况、介入治疗临床效果和预后情况。
Objective To investigate the value of end-stage liver disease scoring system in the interventional treatment of patients with advanced liver cancer. Methods Fifty-eight patients with advanced hepatocellular carcinoma (HCC) were divided into two groups according to the model of end-stage liver disease: 30 cases in study group 1 (30-39 points) and 28 cases in study group 2 (score≥40 points). Both groups were given interventional therapy of advanced liver cancer, Group before and after treatment of patients with clinical biochemical indicators and interventional treatment after 3 months of mortality, analysis of clinical and biochemical indicators of patient mortality and mortality and end-stage liver disease model score. Results The improvement of clinical biochemical indexes in study group 1 was significantly better than that of study group 2 (P <0.05). The mortality of study group 2 was significantly higher than that of study group 1 (P <0.05). Conclusion The end-stage liver disease model score can be used to evaluate the liver function in patients with advanced liver cancer, the clinical effect and prognosis of interventional therapy.